00:28:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.

Kalender

2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020
2022-09-16 08:29:50
OSLO/LONDON, 16 September 2022: EXACT Therapeutics AS ("EXACT-Tx", Euronext
Growth: EXTX), a clinical stage precision health company utilising Acoustic
Cluster Therapy (ACT®) across multiple therapeutic areas, today announced the
appointment of Dr Amir Snapir as Chief Medical Officer (CMO), effective 21
September 2022.

"We are delighted to welcome Amir to EXACT-Tx as CMO. His extensive experience
in clinical development and thorough understanding of the regulatory and
clinical framework for drug-device combinations will be pivotal for our further
development of ACT®.", said Dr Per Walday, CEO of EXACT-Tx. "We continue to
build a strong organisation with clinical and regulatory expertise for
excellence in development strategy and execution. We are very happy to have Amir
in this critical leadership role for the future development of ACT®".

Dr Snapir has a PhD from the University of Turku, Finland and an MD from the
University of Tel Aviv, Israel. He has extensive experience in global clinical
development of novel therapeutics, from early clinical translation to marketing
authorisation, combined with extensive international regulatory experience. Dr
Snapir also has years of experience in business collaborations, alliances and
product co-developments. Dr Snapir comes from the position as CMO of PCI Biotech
where he was responsible for the clinical development of drug-device combination
product candidates. From 2007 to 2020 he held various positions at Orion Pharma,
Espoo, Finland, spanning from leader of clinical pharmacogenomics to clinical
development leader in Oncology. Dr Snapir is the author of numerous scientific
publications.

ENDS

For more information, please contact:

Dr Per Walday
Chief Executive Officer
EXACT-Tx

Email: per.walday@exact-tx.com

About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.